Overview

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Diphenhydramine
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Promethazine
Ramucirumab